URBAN, MARIA LETIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.845
EU - Europa 3.459
AS - Asia 3.410
SA - Sud America 636
AF - Africa 111
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.499
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.771
RU - Federazione Russa 1.435
CN - Cina 882
SG - Singapore 880
IT - Italia 649
HK - Hong Kong 519
BR - Brasile 507
VN - Vietnam 352
KR - Corea 293
IE - Irlanda 273
PL - Polonia 207
SE - Svezia 207
FR - Francia 170
DE - Germania 128
IN - India 108
FI - Finlandia 103
GB - Regno Unito 68
AR - Argentina 61
IQ - Iraq 57
ID - Indonesia 55
JP - Giappone 51
CH - Svizzera 49
BD - Bangladesh 44
NL - Olanda 43
ES - Italia 41
JO - Giordania 41
AU - Australia 34
CA - Canada 33
MX - Messico 27
ZA - Sudafrica 21
UA - Ucraina 20
CI - Costa d'Avorio 18
EC - Ecuador 17
IR - Iran 17
TR - Turchia 17
PY - Paraguay 16
UZ - Uzbekistan 14
BE - Belgio 13
NG - Nigeria 13
AT - Austria 12
EG - Egitto 12
PK - Pakistan 12
PT - Portogallo 11
KE - Kenya 10
CL - Cile 9
CO - Colombia 8
MA - Marocco 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
BJ - Benin 7
TW - Taiwan 7
DZ - Algeria 6
MY - Malesia 6
TH - Thailandia 6
VE - Venezuela 6
GR - Grecia 5
HU - Ungheria 5
LY - Libia 5
PH - Filippine 5
TN - Tunisia 5
UY - Uruguay 5
AM - Armenia 4
AZ - Azerbaigian 4
NP - Nepal 4
PE - Perù 4
BO - Bolivia 3
CR - Costa Rica 3
JM - Giamaica 3
NZ - Nuova Zelanda 3
SN - Senegal 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
HN - Honduras 2
KH - Cambogia 2
LB - Libano 2
MK - Macedonia 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
BY - Bielorussia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
GD - Grenada 1
HR - Croazia 1
IL - Israele 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MU - Mauritius 1
MZ - Mozambico 1
PA - Panama 1
Totale 12.494
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.310
Ashburn 707
Singapore 644
Hong Kong 453
Seoul 293
Dublin 273
Hefei 255
Fairfield 233
San Jose 209
Warsaw 203
Chandler 192
Beijing 168
Ho Chi Minh City 130
Florence 103
Seattle 101
Woodbridge 100
Buffalo 97
Houston 97
Moscow 97
Hanoi 84
Los Angeles 83
Lawrence 80
Lauterbourg 77
Altamura 76
Cambridge 73
The Dalles 72
Wilmington 71
New York 70
Ann Arbor 68
Helsinki 65
Mumbai 60
Paris 56
Boston 54
Princeton 54
Dallas 51
Council Bluffs 46
Bern 41
Munich 40
São Paulo 40
Rome 39
Baghdad 37
Kent 35
Milan 35
Melbourne 33
Tokyo 33
Shanghai 29
Jakarta 28
San Diego 25
Chicago 22
Guangzhou 22
Frankfurt am Main 21
Orem 20
Bengaluru 19
Lappeenranta 19
Abidjan 18
Boardman 18
Medford 18
Montreal 16
Rio de Janeiro 16
Turku 16
London 15
Da Nang 14
Haiphong 14
Tashkent 14
Brussels 13
Brooklyn 12
Biên Hòa 11
Falls Church 11
Abuja 10
Belo Horizonte 10
Chennai 10
Redondo Beach 10
Vienna 10
Cagliari 9
Johannesburg 9
Phoenix 9
Arezzo 8
Bologna 8
Dong Ket 8
Düsseldorf 8
Fossalunga 8
Mexico City 8
Monza 8
Norwalk 8
Nuremberg 8
Quito 8
San Francisco 8
Stockholm 8
Yubileyny 8
Andover 7
Asunción 7
Brasília 7
Clifton 7
Cotonou 7
Hillsboro 7
Poplar 7
Sorocaba 7
Sumaré 7
Tianjin 7
Zurich 7
Totale 7.807
Salva come PNG Salva come JPEG
Nome #
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 260
Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: Data from a tertiary dedicated centre 259
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 243
Anifrolumab In Refractory Systemic Lupus Erythematosus: A Real-Life, Multicenter Study 224
Brief Report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein purpura) 215
IgG4-related disease and other fibro-inflammatory conditions 210
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 210
Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature 208
A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome 194
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting 191
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis 189
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study 188
Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: A multicentre study 183
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre 182
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 181
OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS 178
Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus 177
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial 174
Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis 174
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 173
ModulAtion of gut Microbiota through nutritional interventions in Behçet's syndrome pAtients: the MAMBA Study 173
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: An uncommon adverse effect? 172
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 171
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience 170
Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients 170
Fibrocytes in Chronic Periaortitis: A Novel Mechanism Linking Inflammation and Fibrosis 169
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 169
135. ATHERO-THROMBOTIC AND VENOUS EVENTS (AVTE) IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A MULTICENTRE STUDY OF 573 ITALIAN PATIENTS 166
Significance of PR3-ANCA Positivity in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) 166
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 166
Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal Fibrosis 163
POS1212 SARS-CoV-2 INFECTION AMONG PATIENTS WITH BEHÇET’S SYNDROME 162
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study 161
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study 159
Rituximab for chronic periaortitis without evidence of IgG4-related disease: A long-term follow-up study of 20 patients 159
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) 157
Optical coherence tomography angiography findings in patients affected by giant cell arteritis, with and without ocular involvement: a pilot study 157
298. RITUXIMAB FOR DIFFICULT-TO-TREAT CHRONIC PARIAORTITIS: A CASE-SERIES OF 20 PATIENTS 156
Neutrophil-mediated mechanisms of damage and in vitro protective effect of colchicine in non-vascular Behçet's syndrome 155
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 154
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS) 151
Association of a polymorphism of the Fcγ-receptor 2A (FCGR2A) gene with chronic periaortitis 150
Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis 147
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 145
Slowly progressive ANCA-associated renal vasculitis. Clinico-pathological characterisation and outcome 144
The impact of environmental factors on aetiopathogenesis and clinical manifestations of Behçet's syndrome 142
Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering 140
Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis 140
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study 138
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 137
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 137
Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study 137
Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? 135
Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome 133
SARS-CoV-2 infection among patients with systemic autoimmune diseases 132
SIRT1 and thrombosis 131
Idiopathic Mediastinal Fibrosis: a Systemic Immune-Mediated Disorder. A Case Series and a Review of the Literature 130
Pathophysiology of IgG4-related disease: A T follicular helper cells disease? 128
Unveiling the efficacy, safety, and tolerability of anti-interleukin-1 treatment in monogenic and multifactorial autoinflammatory diseases 128
Epigenetics in autoimmune diseases: Unraveling the hidden regulators of immune dysregulation 126
The management of transitional care of patients affected by phenylketonuria in Italy: Review and expert opinion 125
Rituximab therapy for chronic periaortitis 124
Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: data from a European Collaborative Study 123
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 120
Idiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approach 116
Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study 111
Towards needed improvements in inherited metabolic medicine in adulthood: The SIMMESN adult metabolic working group and MetabERN Joint Position Statement 110
FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis 109
Pharmacological interventions for the prevention of fetal growth restriction: a systematic review and network meta-analysis 108
Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis 105
Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis 104
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients 103
Editorial: New insights into pathophysiology and management of pregnancy in systemic autoimmune diseases: Toward new therapeutic approaches 100
Evidence of subclinical atherosclerosis in Eosinophilic Granulomatosis with Polyangiitis (EGPA) 100
Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases 95
Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives 95
Long-term outcome of a cohort of Italian patients affected with alpha-Mannosidosis 93
The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases 90
Systemic Fibroinflammatory Disorders - Diffuse (Thoraco-Abdominal) Periaortitis 90
Association between idiopathic retroperitoneal fibrosis and autoimmune thyroiditis: A case–control study 88
Treatment of idiopathic retroperitoneal fibrosis 86
Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study 86
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial 73
Impact of mepolizumab on the AAV-PRO questionnaire in eosinophilic granulomatosis with polyangiitis: data from a European multicentre study 67
Fibrosis - A Common Pathway to Organ Injury and Failure 65
Fc gamma-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 57
Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0) 22
Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis with Polyangiitis: Findings from a Large European Cohort 17
Glucocorticoids vs glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis without poor-prognosis factors: a target trial emulation study 12
Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial 5
Recombinant hf-SCIg in inflammatory myositis: refining patient selection and outcome assessment. Author’s reply 5
Totale 12.643
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.546
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.546
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202177 0 0 0 0 0 0 0 0 0 0 37 40
2021/2022513 25 9 85 19 15 56 14 42 29 20 87 112
2022/20231.179 90 255 72 53 50 203 170 68 106 12 41 59
2023/2024619 13 39 74 40 48 78 35 113 20 80 38 41
2024/20254.341 147 424 240 662 1.067 548 155 287 181 174 191 265
2025/20265.050 608 715 670 695 487 179 572 277 322 334 191 0
Totale 12.643